Complex structural variation is prevalent and highly pathogenic in pediatric solid tumors.

CGRs WGS chromoplexy chromothripsis complex genomic rearrangements complex structural variation ecDNA extrachromosomal DNA pediatric solid tumors whole-genome sequencing

Journal

Cell genomics
ISSN: 2666-979X
Titre abrégé: Cell Genom
Pays: United States
ID NLM: 9918284260106676

Informations de publication

Date de publication:
10 Oct 2024
Historique:
received: 18 12 2023
revised: 28 06 2024
accepted: 19 09 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 15 10 2024
Statut: aheadofprint

Résumé

In pediatric cancer, structural variants (SVs) and copy-number alterations contribute to cancer initiation as well as progression, thereby aiding diagnosis and treatment stratification. Although suggested to be of importance, the prevalence and biological relevance of complex genomic rearrangements (CGRs) across pediatric solid tumors is largely unexplored. In a cohort of 120 primary tumors, we systematically characterized patterns of extrachromosomal DNA, chromoplexy, and chromothripsis across five pediatric solid cancer types. CGRs were identified in 56 tumors (47%), and in 42 of these tumors, CGRs affect cancer driver genes or result in unfavorable chromosomal alterations. This demonstrates that CGRs are prevalent and pathogenic in pediatric solid tumors and suggests that selection likely contributes to the structural variation landscape. Moreover, carrying CGRs is associated with more adverse clinical events. Our study highlights the potential for CGRs to be incorporated in risk stratification or exploited for targeted treatments.

Identifiants

pubmed: 39406233
pii: S2666-979X(24)00294-5
doi: 10.1016/j.xgen.2024.100675
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100675

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Ianthe A E M van Belzen (IAEM)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Marc van Tuil (M)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Shashi Badloe (S)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Alex Janse (A)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Eugène T P Verwiel (ETP)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Marcel Santoso (M)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Sam de Vos (S)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

John Baker-Hernandez (J)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Hindrik H D Kerstens (HHD)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Nienke Solleveld-Westerink (N)

Department of Pathology, UMC Utrecht, Utrecht, the Netherlands.

Michael T Meister (MT)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.

Jarno Drost (J)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.

Marry M van den Heuvel-Eibrink (MM)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; UMC Utrecht-Wilhelmina Children's Hospital-Child Health, Utrecht, the Netherlands.

Johannes H M Merks (JHM)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Division of Imaging and Oncology, UMC Utrecht and Utrecht University, Utrecht, the Netherlands.

Jan J Molenaar (JJ)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

Weng Chuan Peng (WC)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Bastiaan B J Tops (BBJ)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Frank C P Holstege (FCP)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Patrick Kemmeren (P)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Center for Molecular Medicine, UMC Utrecht and Utrecht University, Utrecht, the Netherlands. Electronic address: p.kemmeren@prinsesmaximacentrum.nl.

Jayne Y Hehir-Kwa (JY)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Electronic address: j.y.hehirkwa@prinsesmaximacentrum.nl.

Classifications MeSH